At Vésale Bioscience, we are driven by a singular purpose: transforming the fight against antimicrobial resistance (AMR). Founded in Belgium in 2018, our mission is to develop evidence-driven, personalized phage-based therapies that provide hope and life-changing care for patients with difficult-to-treat infections.

AMR is one of the most pressing global health challenges. Bacteriophages, natural viruses that target and destroy bacteria, offer a groundbreaking solution. Vésale Bioscience is pioneering innovative, personalized, and sustainable phage-antibiotic therapies designed to combat multi-resistant bacterial infections with unmatched precision and efficiency.

Recognized as Europe’s most innovative life sciences start-up in 2021, we were awarded €1.8 million by the European Innovation Council in 2023 to accelerate our research. Our approach combines selective wild-type phages, advanced diagnostics, and decision-support tools to deliver tailored treatments within 24 hours, addressing each patient’s unique infection needs.

Our ambition is clear: to treat patients with complex infections starting in 2026 and to expand our impact to more than 10,000 patients across 100 European reference centers by 2030. We are not just innovating – we are restoring hope and redefining care for the AMR era.

The company has forged strategic partnerships with university researchers, KOLs (Key Opinion Leaders), hospitals, reference centres and industry to achieve this goal. The aim is also to make these therapies accessible to all patients, improving their health and quality of life.

For more information, sent an e-mail to info@phage.health.

We are actively looking for commercial partners for our current assets. Many territories are still open for licensing/distribution agreements.

Contact for partnerships
Please submit your business development proposals via email to info@phage.health